Mark Odaniel
Psychiatry · Rocky Mount, NCNPI 1164529640
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,800 of the $29,765 with a category attached, or 80.0%. AbbVie accounts for 88.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $13,536 and has fallen 95.7% since, to $579 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $96.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Teva Pharmaceuticals USA, Inc.$799
- Johnson & Johnson$624
- Alkermes, Inc.$408
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$361
- Otsuka America Pharmaceutical, Inc.$361
- plus $874 from 15 others
What the payments were for
- Speaking & faculty fees$23,80080%
- Travel & lodging$1,6275%
- Food & beverage$4,13714%
- Education$2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $26,338 |
| Teva Pharmaceuticals USA, Inc. | 55 | $799 |
| Johnson & Johnson(2 entities) | 31 | $624 |
| Alkermes, Inc. | 29 | $408 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $361 |
| Otsuka America Pharmaceutical, Inc. | 23 | $361 |
| E.r. Squibb & Sons, L.L.C. | 13 | $210 |
| Ironshore Pharmaceuticals Inc. | 6 | $117 |
| Neurocrine Biosciences, Inc. | 7 | $117 |
| Vanda Pharmaceuticals Inc. | 6 | $113 |
| Luye Pharma (USA) Ltd. | 3 | $49 |
| Indivior Inc. | 2 | $45 |
| Almatica Pharma LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $33 |
| Merz North America, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Merck | 1 | $19 |
| Neuronetics, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,765 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 93 | $232,897 |
| Abilify MaintenaAripiprazole | 65 | $189,397 |
| VraylarCariprazine Hcl | 108 | $153,097 |
| AustedoDeutetrabenazine | 18 | $111,833 |
| Austedo XrDeutetrabenazine | 12 | $77,365 |
| Risperidone ErRisperidone Microspheres | 12 | $23,608 |
| RexultiBrexpiprazole | 13 | $19,183 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $8,607 |
| Chlorpromazine Hcl | 39 | $7,361 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,914 |
| Fluphenazine Hcl | 44 | $3,869 |
| Clozapine | 40 | $3,370 |
| Haloperidol Decanoate | 68 | $3,283 |
| Fluphenazine Decanoate | 12 | $2,317 |
| Benztropine Mesylate | 232 | $2,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $624 | $232,89793 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $361 | $208,57978 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $799 | $189,19830 claims |
| AbbVieVraylar | $26,338 | $153,097108 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $38 | $14,52136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Rocky Mount
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
- David JoyeAlbemarle$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.